

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Beijing Luzhu Biotechnology Co., Ltd.

北京綠竹生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2480)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2025

Reference is made to the annual report of Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the year ended December 31, 2025 (the “**2025 Annual Report**”) published on April 23, 2026. Unless otherwise defined or the context otherwise requires, terms used herein shall bear the same meanings as those defined in the 2025 Annual Report.

Further to the information provided in the 2025 Annual Report, the Company would like to (i) provide the shareholders of the Company and potential investors with the following supplemental information in relation to the 2025 Share Award Scheme; and (ii) clarify certain information in relation to the paragraph headed “Equity Linked Agreements” in the section headed “Report of the Directors” of the 2025 Annual Report.

Maximum entitlement of each participant under the 2025 Share Award Scheme pursuant to 17.09(4) of the Listing Rules

No Awards shall be granted to any eligible participant(s) if such grant of Awards to such person, if vested, would result in that selected participant becoming entitled to subscribe for such number of Shares as, when aggregated with the total number of Shares already issued or to be issued to him/her upon exercise of all Awards and other scheme options and awards granted to him/her in the 12-month period up to and including the date of such grant to exceed 1% of the number of Shares in issue (excluding treasury Shares) as of that the date of such grant, unless such grant has been duly approved by Shareholders of the Company in general meeting in accordance with the rules of the 2025 Share Award Scheme.

Equity Linked Agreements

The Company would like to clarify the disclosures under the paragraph headed “Equity Linked Agreements” in the section headed “Report of the Directors” on page 40 of the 2025 Annual Report should read as (with amendments underlined):

“Save for the 2025 Share Award Scheme, no equity-linked agreements that will or may result in the Company issuing Shares nor require the Company to enter into an agreement that will or may result in the Company issuing Shares was entered into by the Company during the Reporting Period or subsisted at the end of the Reporting Period.”

The supplemental information in this announcement does not affect other information contained in the 2025 Annual Report. Save as disclosed in this announcement, the remaining content of the 2025 Annual Report remains unchanged.

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, September 24, 2026

As of the date of this announcement, the Board comprises Mr. KONG Jian, Ms. PENG Ling and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Ms. HOU Aijun, Mr. LEUNG Wai Yip and Mr. LIANG Yeshe as independent non-executive Directors.